BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $25,201,760 | +108.2% | 370,233 | +149.6% | 0.01% | +100.0% |
| Q2 2023 | $12,106,300 | -72.1% | 148,307 | -74.6% | 0.00% | -66.7% |
| Q1 2023 | $43,383,641 | +444.8% | 584,764 | +508.6% | 0.01% | +350.0% |
| Q4 2022 | $7,963,691 | -79.1% | 96,087 | -28.3% | 0.00% | -77.8% |
| Q3 2022 | $38,037,000 | +555.1% | 133,932 | +699.5% | 0.01% | +350.0% |
| Q2 2022 | $5,806,000 | -81.3% | 16,751 | -76.6% | 0.00% | -66.7% |
| Q1 2022 | $31,066,000 | +138.8% | 71,738 | +185.3% | 0.01% | +200.0% |
| Q4 2021 | $13,011,000 | -54.8% | 25,148 | -57.6% | 0.00% | -66.7% |
| Q3 2021 | $28,757,000 | +16.0% | 59,345 | +7.8% | 0.01% | +20.0% |
| Q2 2021 | $24,791,000 | +178.3% | 55,060 | +136.0% | 0.01% | +150.0% |
| Q1 2021 | $8,909,000 | -2.7% | 23,327 | -19.1% | 0.00% | -33.3% |
| Q4 2020 | $9,157,000 | +73.5% | 28,836 | +35.3% | 0.00% | +50.0% |
| Q3 2020 | $5,279,000 | -72.4% | 21,310 | -70.5% | 0.00% | -66.7% |
| Q2 2020 | $19,105,000 | +1027.1% | 72,346 | +709.0% | 0.01% | +500.0% |
| Q1 2020 | $1,695,000 | -87.0% | 8,943 | -85.0% | 0.00% | -83.3% |
| Q4 2019 | $13,064,000 | +797.3% | 59,517 | +699.7% | 0.01% | +500.0% |
| Q3 2019 | $1,456,000 | -91.3% | 7,442 | -90.7% | 0.00% | -87.5% |
| Q2 2019 | $16,647,000 | -26.5% | 79,845 | -30.1% | 0.01% | -27.3% |
| Q1 2019 | $22,664,000 | +288.4% | 114,150 | +183.1% | 0.01% | +266.7% |
| Q4 2018 | $5,835,000 | -27.2% | 40,316 | +2.7% | 0.00% | -25.0% |
| Q3 2018 | $8,010,000 | +4.4% | 39,243 | -24.3% | 0.00% | 0.0% |
| Q2 2018 | $7,670,000 | -27.2% | 51,841 | -25.7% | 0.00% | -33.3% |
| Q1 2018 | $10,541,000 | -80.5% | 69,791 | -83.3% | 0.01% | -81.8% |
| Q4 2017 | $53,988,000 | +38.0% | 416,736 | +28.8% | 0.03% | +10.0% |
| Q3 2017 | $39,115,000 | +3.1% | 323,561 | +0.2% | 0.03% | -6.2% |
| Q2 2017 | $37,952,000 | +34.9% | 322,994 | +16.7% | 0.03% | +23.1% |
| Q1 2017 | $28,133,000 | +82.6% | 276,762 | +84.8% | 0.03% | +62.5% |
| Q4 2016 | $15,404,000 | +11.6% | 149,791 | +18.8% | 0.02% | +14.3% |
| Q3 2016 | $13,808,000 | +68.2% | 126,093 | +73.2% | 0.01% | +55.6% |
| Q2 2016 | $8,210,000 | +28.0% | 72,805 | +7.3% | 0.01% | +12.5% |
| Q1 2016 | $6,413,000 | -7.1% | 67,844 | -11.5% | 0.01% | 0.0% |
| Q4 2015 | $6,903,000 | -2.1% | 76,698 | +0.6% | 0.01% | +14.3% |
| Q3 2015 | $7,048,000 | -27.7% | 76,225 | -23.0% | 0.01% | -12.5% |
| Q2 2015 | $9,747,000 | -28.3% | 98,986 | -27.0% | 0.01% | -38.5% |
| Q1 2015 | $13,599,000 | -13.1% | 135,596 | -19.9% | 0.01% | -13.3% |
| Q4 2014 | $15,648,000 | – | 169,351 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |